Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 1/2018

Open Access 01-06-2018 | Case Series

Treatment with Botulinum Toxin for Refractory Fever Caused by Severe Spasticity: A Case Series

Authors: Jacobo Lester, Gerardo Esteban Alvarez-Resendiz, Enrique Klériga, Fernando Videgaray, Gerardo Zambito

Published in: Neurology and Therapy | Issue 1/2018

Login to get access

Abstract

Introduction

Brain and spinal cord injuries may cause very severe spasticity that occasionally may be associated with persistent fever.

Case Series

We present 14 patients with spasticity and persistent fever, treated with botulinum toxin type A. Their spasticity improved and the fever resolved within a period no greater than 48 h. In all cases, infectious and other non-infectious causes were ruled out.

Conclusions

When sustained tonic muscular activity is associated with a significant increase in body temperature and is refractory to the usual drugs used for hyperpyrexia, type A botulinum toxin may be an effective treatment option to control both spasticity and fever.
Literature
1.
Sneed RC. Hyperpyrexia associated with sustained muscle contractions: an alternative diagnosis to central fever. Arch Phys Med Rehabil. 1995;76:101–3.CrossRefPubMed
2.
Mandac BR, Hurvitz EA, Nelson VS. Hyperthermia associated with baclofen withdrawal and increased spasticity. Arch Phys Med Rehabil. 1993;74:96–7.PubMed
3.
Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961;40:1–30.CrossRef
4.
Clifton GL, Ziegler MG, Grossman RG. Circulating catecholamines and sympathetic activity after head injury. Neurosurgery. 1981;8:10–4.CrossRefPubMed
5.
Lump D, Moyer M. Paroxysmal sympathetic hyperactivity after severe brain injury. Curr Neurol Neurosci Rep. 2014;14:494.CrossRefPubMed
6.
Saxena M, Young P, Pilcher D. Early temperature and mortality in critically ill patients with acute neurological diseases: trauma and stroke differ from infection. Intensive Care Med. 2015;41:823–32.CrossRefPubMedPubMedCentral
7.
Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke. 2008;39:3029–35.CrossRefPubMed
8.
Heiman-Patterson TD. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am. 1993;77:477–92.CrossRefPubMed
9.
Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 1980;30:1303–13.CrossRefPubMed
10.
Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, et al. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-interdisciplinary working group for movement disorders task force. J Neurol. 2017;264:112–20.CrossRefPubMed
11.
12.
13.
Zhao X, Song Q, Gao Y. Hypothesis: exertional heat stroke-induced myopathy and genetically inherited malignant hyperthermia represent the same disorder, the human stress syndrome. Cell Biochem Biophys. 2014;70:1325–9.CrossRefPubMed
14.
15.
Bohannon RW, Smith MB. Interrater reliability of a modified ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–7.CrossRefPubMed
16.
Pérez-Arredondo A, Cázares-Ramírez E, Carrillo-Mora P, Martínez-Vargas M, Cárdenas-Rodríguez N, Coballase-Urrutia E, et al. Baclofen in the therapeutic of sequele of traumatic brain injury: spasticity. Clin Neuropharmacol. 2016;39:311–9.CrossRefPubMedPubMedCentral
17.
Denborough MA, Forster JFA, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth. 1962;34:395–6.CrossRefPubMed
18.
Feuerman T, Gade GF, Reynolds R. Stress-induced malignant hyperthermia in a head-injured patient. Case report. J Neurosurg. 1988;68:297–9.CrossRefPubMed
19.
Steele SR, Martin MJ, Mullenix PS, Long WB, Gubler KD. Fatal malignant hyperpyrexia in a cervical spine- injured patient. J Trauma. 2005;58:375–7.CrossRefPubMed
20.
Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology. 2001;94:95–100.CrossRefPubMed
21.
22.
Blackman JA, Patrick PD, Buck ML, Rust RS Jr. Paroxysmal autonomic instability with dystonia after brain injury. Arch Neurol. 2004;61:321–8.CrossRefPubMed
23.
Harrison GG. Malignant hyperthermia. Dantrolene-dynamics and kinetics. Br J Anaesth. 1988;60:279–86.CrossRefPubMed
24.
Wenham T, Cohen A. Botulism. Contin Educ Anaesth Crit Care Pain. 2008;8:21–5.CrossRef
25.
de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA. 1999;96:3200–5.CrossRefPubMedPubMedCentral
Metadata
Title
Treatment with Botulinum Toxin for Refractory Fever Caused by Severe Spasticity: A Case Series
Authors
Jacobo Lester
Gerardo Esteban Alvarez-Resendiz
Enrique Klériga
Fernando Videgaray
Gerardo Zambito
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 1/2018
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-018-0092-1

Other articles of this Issue 1/2018

Neurology and Therapy 1/2018 Go to the issue

Commentary

Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives

Original Research

ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs

Brief Report

Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches

Letter

Author’s Response to the Letter to the Editor Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives

Editorial

Editorial Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives

Correction

Correction to: Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study